USC Norris study validates way to improve breast cancer survival
A new study from the USC Norris Comprehensive Cancer Center shows targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer patients significantly increased overall survival times.
A team of researchers led by Debu Tripathy, professor of medicine at the Keck School of Medicine of USC, looked at data provided by RegistHER, a prospective, observational study of 1,023 newly diagnosed HER2-positive metastatic breast cancer patients. … Read More »